295 related articles for article (PubMed ID: 17519147)
1. The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials.
Roumen FJ
Contraception; 2007 Jun; 75(6):420-9. PubMed ID: 17519147
[TBL] [Abstract][Full Text] [Related]
2. Skin patch and vaginal ring versus combined oral contraceptives for contraception.
Lopez LM; Grimes DA; Gallo MF; Stockton LL; Schulz KF
Cochrane Database Syst Rev; 2013 Apr; 2013(4):CD003552. PubMed ID: 23633314
[TBL] [Abstract][Full Text] [Related]
3. Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study.
Duijkers IJ; Klipping C; Verhoeven CH; Dieben TO
Hum Reprod; 2004 Nov; 19(11):2668-73. PubMed ID: 15333593
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial.
Oddsson K; Leifels-Fischer B; de Melo NR; Wiel-Masson D; Benedetto C; Verhoeven CH; Dieben TO
Contraception; 2005 Mar; 71(3):176-82. PubMed ID: 15722066
[TBL] [Abstract][Full Text] [Related]
5. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial.
Oddsson K; Leifels-Fischer B; Wiel-Masson D; de Melo NR; Benedetto C; Verhoeven CH; Dieben TO
Hum Reprod; 2005 Feb; 20(2):557-62. PubMed ID: 15539438
[TBL] [Abstract][Full Text] [Related]
6. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
Ahrendt HJ; Nisand I; Bastianelli C; Gómez MA; Gemzell-Danielsson K; Urdl W; Karskov B; Oeyen L; Bitzer J; Page G; Milsom I
Contraception; 2006 Dec; 74(6):451-7. PubMed ID: 17157101
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
[TBL] [Abstract][Full Text] [Related]
9. Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of a contraceptive vaginal ring and an oral contraceptive.
Roumen FJ; Dieben TO
Fertil Steril; 2006 Jan; 85(1):57-62. PubMed ID: 16412731
[TBL] [Abstract][Full Text] [Related]
10. Skin patch and vaginal ring versus combined oral contraceptives for contraception.
Lopez LM; Grimes DA; Gallo MF; Schulz KF
Cochrane Database Syst Rev; 2008 Jan; (1):CD003552. PubMed ID: 18254023
[TBL] [Abstract][Full Text] [Related]
11. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive.
van den Heuvel MW; van Bragt AJ; Alnabawy AK; Kaptein MC
Contraception; 2005 Sep; 72(3):168-74. PubMed ID: 16102549
[TBL] [Abstract][Full Text] [Related]
12. Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables.
Rad M; Kluft C; Ménard J; Burggraaf J; de Kam ML; Meijer P; Sivin I; Sitruk-Ware RL
Am J Obstet Gynecol; 2006 Jul; 195(1):72-7. PubMed ID: 16545330
[TBL] [Abstract][Full Text] [Related]
13. The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study.
Tuppurainen M; Klimscheffskij R; Venhola M; Dieben TO
Contraception; 2004 May; 69(5):389-94. PubMed ID: 15105061
[TBL] [Abstract][Full Text] [Related]
14. Skin patch and vaginal ring versus combined oral contraceptives for contraception.
Lopez LM; Grimes DA; Gallo MF; Schulz KF
Cochrane Database Syst Rev; 2010 Mar; (3):CD003552. PubMed ID: 20238323
[TBL] [Abstract][Full Text] [Related]
15. Review of the combined contraceptive vaginal ring, NuvaRing.
Roumen FJ
Ther Clin Risk Manag; 2008 Apr; 4(2):441-51. PubMed ID: 18728840
[TBL] [Abstract][Full Text] [Related]
16. Yasmin: the reason why.
Thorneycroft IH
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
[TBL] [Abstract][Full Text] [Related]
17. The vaginal contraceptive pill.
Coutinho E
IPPF Med Bull; 1985 Feb; 19(1):2-3. PubMed ID: 12339969
[TBL] [Abstract][Full Text] [Related]
18. Complete and robust ovulation inhibition with NuvaRing.
Killick S
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 2():13-8; discussion 37-9. PubMed ID: 12659397
[TBL] [Abstract][Full Text] [Related]
19. Skin patch and vaginal ring versus combined oral contraceptives for contraception.
Gallo MF; Grimes DA; Schulz KF
Cochrane Database Syst Rev; 2003; (1):CD003552. PubMed ID: 12535478
[TBL] [Abstract][Full Text] [Related]
20. Lower hormone dosage with improved cycle control.
Vree M
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 2():25-30; discussion 37-9. PubMed ID: 12659399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
